|Mr. Hamza Suria||Pres, CEO & Director||573.54k||3.57M||1976|
|Mr. Eric J. Loumeau||COO & Gen. Counsel||480.76k||N/A||1963|
|Mr. Dennis M. Mulroy||Chief Financial Officer||N/A||N/A||1955|
|Ms. Beth Mueller||Sr. VP of HR||N/A||N/A||N/A|
|Dr. Margaret Marino||Sr. VP of Project Management||N/A||N/A||N/A|
|Dr. Paul F. Lizzul||Chief Medical Officer||N/A||N/A||1975|
|Mr. David McKeon||VP & Controller||N/A||N/A||1972|
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis and palmoplantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd.; collaboration with Celgene Corporation; and immuno-oncology collaboration agreement with GlaxoSmithKline plc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.
AnaptysBio, Inc.’s ISS Governance QualityScore as of December 2, 2020 is 9. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 9.